Search PubMed⌕ Search

Biomedical subjects

W Hennessen

Publications and source records attributed to W Hennessen.

At least 37 records · Page 2Linked to original sources

[Epidemiological effect of influenza vaccination (author's transl)].

No influenza-A virus epidemic occurred in the Federal Republic of Germany during 1971-1975. The neighbouring countries, however, reported up to three such epidemics. The vaccines used had differences: contrary to neighbouring countries, in the FRG largely those were used which had mineral adjuvants, and they more frequently had viral subgroups. Comparison between the USA and FRG with respect to influenza death-rates over 20 years revealed a strict correlation from 1956 up to 1965. But since 1966 the death-rate has decreased progressively in the FRG while it has remained unchanged in the USA. Immunisation methods in the two countries have differed since 1966 in that the Public Health Authorities of the two countries have recommended immunisation of different population groups: in the USA it has been only for patients at risk, while in the FRG the rest of the population has also been urged to be immunised. As a result, immunisation rates differ markedly between the two countries. Absence of an influenza epidemic, accompanied by a reduction in death-rate due to influenza, strongly suggests that the two phenomena are the result of a break in the infection chain. This seems to be more successful when both part of the total population and the risk groups are immunised.

Cross-Cultural Comparison↗

[Developments in vaccines for prophylactic use (author's transl)].

The epidemiologic background on which the efficacy of vaccines has to be considered shows that the mortality of infectious diseases in the first seventy years of our century was reduced to an extent which goes far beyond all other diseases. This trend is similar in all countries of comparable status of zivilization. Trends in morbidity may be different, but no sufficient documentation is available for morbidity of infectious diseases in this country. Developments of new vaccines for industrialized countries will show a change compared with the present vaccines. After introduction of vaccines against the big killers until 1950 disabling diseases were the more recent target of immunoprophylaxis such as poliomyelitis, measles, rubella, mumps. Vaccine efficiency was greatly increased by vaccination campaigns for which strategies and tactics were developed in an almost military fashion. Analysis of the future vaccines reveals a further change not only by additional antigens but by new target groups of the population to be protected. Not only will more vaccines be developed for adults but also for certain risk groups. More knowledge of immune-defence mechanisms in such groups will be needed for the final success of such vaccines. Moreover immunoprophylaxis may even enable immunotherapy in future. The most dramatic effect of immunoprophylaxis is to be expected in the coming decades in the non-industrialized world. This will be effectuated not by the newer vaccines, but by products which we know already. It is the decision of WHO to include an "Expanded program of vaccination" into their help for developing countries. Here new technologies are under investigation which will procure a new round in vaccination tactics. Vaccination is planned by WHO not only to help to develop countries but to play a decisive role in the problem of over-population. Such expectations are based on the fact that in the industrialized world the birthrate fell while the infant survival rates rose. Vaccination then would be more than immunoprophylaxis; vaccination would have a place then among man's many intelligent answers to mankind's many natural problems.

Adolescent↗

Freeze-drying of a purified human diploid cell rabies vaccine.

A rabies vaccine prepared in human diploid cell strains was purified by continuous-flow sucrose density gradient centrifugation. The peak fractions containing 35-40% sucrose were diluted with a stabilizer consisting of degraded gelatine in a Tris-EDTA-buffer, and then inactivated with beta-propiolactone and freeze-dried to a residual moisture of approximately 2.5%. This vaccine was stable as proved by accelerated stability tests.

Cell Line↗